MX2018007681A - Composicion farmaceutica osmotica oral de vildagliptin. - Google Patents
Composicion farmaceutica osmotica oral de vildagliptin.Info
- Publication number
- MX2018007681A MX2018007681A MX2018007681A MX2018007681A MX2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A
- Authority
- MX
- Mexico
- Prior art keywords
- vildagliptin
- pharmaceutical composition
- salt
- surrounding
- osmotic pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4891MU2015 | 2015-12-28 | ||
| PCT/IB2016/057975 WO2017115252A1 (en) | 2015-12-28 | 2016-12-23 | An oral osmotic pharmaceutical composition of vildagliptin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018007681A true MX2018007681A (es) | 2018-11-14 |
Family
ID=57966046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007681A MX2018007681A (es) | 2015-12-28 | 2016-12-23 | Composicion farmaceutica osmotica oral de vildagliptin. |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20180092981A (pt) |
| BR (1) | BR112018013195A2 (pt) |
| MX (1) | MX2018007681A (pt) |
| PH (1) | PH12018550075A1 (pt) |
| RU (1) | RU2706706C1 (pt) |
| WO (1) | WO2017115252A1 (pt) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| AU2003262059A1 (en) | 2002-09-11 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| CA2622579C (en) | 2005-09-20 | 2013-12-31 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| EP2259676A4 (en) * | 2008-03-04 | 2011-03-16 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
| EP2578208B1 (en) | 2011-10-06 | 2014-05-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
| RU2015105097A (ru) | 2012-08-23 | 2016-10-10 | Кардиолинкс Аг | Композиции аминоалкилнитрата с пролонгированным высвобождением |
-
2016
- 2016-12-23 WO PCT/IB2016/057975 patent/WO2017115252A1/en active Application Filing
- 2016-12-23 RU RU2018120202A patent/RU2706706C1/ru not_active IP Right Cessation
- 2016-12-23 KR KR1020187016451A patent/KR20180092981A/ko unknown
- 2016-12-23 BR BR112018013195A patent/BR112018013195A2/pt not_active Application Discontinuation
- 2016-12-23 MX MX2018007681A patent/MX2018007681A/es unknown
-
2018
- 2018-06-01 PH PH12018550075A patent/PH12018550075A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018013195A2 (pt) | 2018-12-11 |
| PH12018550075A1 (en) | 2019-01-28 |
| RU2706706C1 (ru) | 2019-11-20 |
| WO2017115252A1 (en) | 2017-07-06 |
| KR20180092981A (ko) | 2018-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015184127A3 (en) | Stable cannabinoid formulations | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| EP3590498A4 (en) | PREPARATION WITH INCLUDING COMPLEX OF VARENICLINE OR PHARMACEUTICAL SAFE SALT THEREOF FOR ORAL ADMINISTRATION | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX2017003561A (es) | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| MX2021004439A (es) | Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma. | |
| WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| PH12016500693A1 (en) | Slow-release solid oral compositions | |
| WO2015125152A3 (en) | Pharmaceutical compositions of asenapine | |
| WO2019194773A3 (en) | The combination comprising linagliptin and metformin | |
| MX2015010486A (es) | Composicion masticable para administracion oral y proceso para preparar la misma. | |
| EP3648745A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| WO2016167605A3 (ko) | 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법 | |
| PH12018550075A1 (en) | An oral osmotic pharmaceutical composition of vildagliptin | |
| CY1125762T1 (el) | Νεα απο του στοματος σκευασματα βελινοστατης | |
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
| EP3898596A4 (en) | PHARMACEUTICAL COMPOUND, METHOD FOR MAKING IT AND ITS USE AS A THERAPEUTIC AGENT | |
| PH12016502527A1 (en) | Stabilized desmopressin | |
| WO2019240700A3 (en) | Oral pharmaceutical compositions of mesalazine |